ZYBT — Zhengye Biotechnology Holding Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for Zhengye Biotechnology Holding, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	20-F	20-F	20-F
Standards:	USG	USG	USG	USG
Status:	Final	Final	Final	Final
Revenue
Total Revenue	0.214	260	212	186
Cost of Revenue
Gross Profit	0.125	148	118	91.3
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	0.162	194	167	170
Operating Profit	0.052	65.8	45	16.4
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	0.053	63.9	43.8	14.4
Provision for Income Taxes
Net Income After Taxes	0.046	55.7	37.5	13.5
Minority Interest
Net Income Before Extraordinary Items
Net Income	0.046	46.7	31.5	11.3
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	0.046	46.7	31.5	11.3
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.001	1.01	0.881	0.373
Dividends per Share